Next step for Xenome
Thursday, 25 September, 2008
Privately held biotech Xenome has begun a Phase II trial of lead candidate Xen2174 for the control of acute post-operative pain.
The trial will enrol approximately 200 patients at multiple clinical sites in the US.
The aim is to evaluate the safety and efficacy of Xen2174 administered as a single intrathecal administration to patients undergoing unilateral bunionectomy, a standard model for the assessment of acute pain therapies.
Xenome is also in Phase II trials of Xen2174 for chronic pain.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
